In its April 2019 piece entitled “Importing Bad Ideas on Drug Prices,“ the Editorial Board of The Wall Street Journal showcases several of the flawed arguments and propaganda techniques employed by the big pharma lobby to undermine the fair, safe and pragmatic practice of importing prescription drugs from Canada. Fortunately, Florida Governor Ron DeSantis and state lawmakers weren’t swayed, and have passed a new law to create a state-based drug importation program.
Prescription Justice is pleased to welcome Colleen Kenny LaRocque to the Board of Directors. The Prescription Justice Board provides leadership for carrying out the organization’s mission to end the crisis of high prescription drug prices in America.
Earlier this week, Prescription Justice founder Gabriel Levitt published an article in The Nation entitled, “Is the FDA Misleading Congress About the Safety of Imported Medicines?”. While we advocate for policies and legislative reforms to bring down drug prices here in the U.S., the article highlights the fact that personal prescription drug importation is already a lifeline for millions of Americans who can’t afford their medications here.
Prescription Justice is very pleased to announce a new addition to our Board of Directors, Lindsay Brown. In 2018, Lindsay ran for the U.S. House of Representatives in the Republican primary in New Jersey's 7th district by championing causes that are important to all Americans, such as lowering prescription drug prices in America! Lindsay is a software and web developer who has worked for media organizations such as the New York Post, where she was a project manager on the digital product team.
“Pursuant to the evidence and reasons given above, I believe my testimony overcomes the FDA’s public health justifications for refusing my medication order and ask that you release it to me. If you don’t then my health may be jeopardized because I can’t afford it locally.” Letter from a patient to the U.S. Food and Drug Administration (FDA) whose arthritis medicine was detained, and subject to refusal by the FDA. Each year, a few million Americans import lower cost medicines because the prices are lower, despite the federal restrictions. Most such orders are received, at least when patients have valid prescriptions, but the FDA has the authority to refuse and destroy them.